The Latest Breaking News from Danaher

A whale with a lot of money to spend has taken a noticeably bearish stance on Danaher. Looking at options history for Danaher (NYSE:DHR) we detected 11 strange trades.

Danaher Corp (NYSE:DHR) logged Q1 FY22 adjusted EPS of $2.76, up 9.5% Y/Y, surpassing the estimate of $2.66. Sales increased 12% to $7.7 billion, with 12% non-GAAP core and 8.0% non-GAAP base business core revenue growth, beating the $7.54 billion estimate. Operating cash flow reached $2 billion. Non-GAAP free cash flow reached…

On Wednesday, Danaher stock got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.

Danaher (NYSE:DHR) has outperformed the market over the past 15 years by 7.23% on an annualized basis producing an average annual return of 15.22%. Currently, Danaher has a market capitalization of $212.45 billion.

Someone with a lot of money to spend has taken a bearish stance on Danaher (NYSE:DHR). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Danaher (NYSE:DHR) has outperformed the market over the past 20 years by 7.58% on an annualized basis.

Rising demand for advanced diagnostic devices for predicting the early development of diseases and getting accurate results within less time should drive the diagnostics and research industry’s growth. Given the rising investments in the industry, prominent players in this space, Thermo Fisher (TMO) and Danaher (DHR) should benefit. But which…

Danaher (NYSE:DHR) has outperformed the market over the past 10 years by 8.65% on an annualized basis.

Nasdaq futures traded sharply lower this morning after Meta Platforms, Inc. (NASDAQ: FB) reported worse-than-expected Q4 EPS results and issued weak forecast.